Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: DRUG: Anastrozole|DRUG: Doxorubicin Hydrochloride|DRUG: Exemestane|OTHER: Laboratory Biomarker Analysis|DRUG: Letrozole|BIOLOGICAL: Pembrolizumab
Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)|Merck Sharp & Dohme LLC